Paradigm Biopharmaceuticals ( ($AU:PAR) ) has provided an announcement.
Paradigm Biopharmaceuticals has agreed with Obsidian Global to redeem and cancel a further 1,171,477 convertible notes for a cash payment of US$1.4 million, leaving 3,125,708 notes outstanding under a secured convertible securities arrangement. The transaction reflects ongoing efforts to manage its capital structure while under voluntary administration and operating within the constraints of existing security over its assets.
The company also provided an update on its Phase 3 PARA_OA_012 osteoarthritis trial, noting that internal review of unblinded data shows missing data at key time points, particularly at U.S. sites, which heavily influences interim results. Preliminary observations from non-U.S. sites appear encouraging but remain inconclusive, the trial will not proceed as previously decided, and Paradigm plans a further update after completion of an independent statistical analysis.
The most recent analyst rating on ($AU:PAR) stock is a Buy
with a A$0.42 price target.
To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock,
see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is an Australian biopharmaceutical company focused on developing therapies, including late-stage clinical programs, for conditions such as osteoarthritis. The company has entered voluntary administration, with joint administrators appointed and its securities remaining suspended from trading on the ASX as it navigates financial and operational challenges.
Average Trading Volume: 2,403,781
Technical Sentiment Signal: Hold
Current Market Cap: A$153.5M
For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.
